CN111491657A - 用于异源蛋白质生产的人工分泌肽 - Google Patents

用于异源蛋白质生产的人工分泌肽 Download PDF

Info

Publication number
CN111491657A
CN111491657A CN201880081319.8A CN201880081319A CN111491657A CN 111491657 A CN111491657 A CN 111491657A CN 201880081319 A CN201880081319 A CN 201880081319A CN 111491657 A CN111491657 A CN 111491657A
Authority
CN
China
Prior art keywords
seq
protein
lactobacillus
amino acid
signal peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880081319.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·黛娜丝
G·彻尔驰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CN111491657A publication Critical patent/CN111491657A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201880081319.8A 2017-10-20 2018-10-19 用于异源蛋白质生产的人工分泌肽 Pending CN111491657A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762575350P 2017-10-20 2017-10-20
US62/575,350 2017-10-20
US201762584367P 2017-11-10 2017-11-10
US62/584,367 2017-11-10
US201862676203P 2018-05-24 2018-05-24
US62/676,203 2018-05-24
US201862691553P 2018-06-28 2018-06-28
US62/691,553 2018-06-28
PCT/US2018/056610 WO2019079663A1 (en) 2017-10-20 2018-10-19 ARTIFICIAL SECRETING PEPTIDES FOR THE PRODUCTION OF HETEROLOGOUS PROTEINS

Publications (1)

Publication Number Publication Date
CN111491657A true CN111491657A (zh) 2020-08-04

Family

ID=66173492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880081319.8A Pending CN111491657A (zh) 2017-10-20 2018-10-19 用于异源蛋白质生产的人工分泌肽

Country Status (6)

Country Link
US (2) US11530433B2 (enExample)
EP (1) EP3697428A4 (enExample)
JP (1) JP7330517B2 (enExample)
KR (1) KR20200077534A (enExample)
CN (1) CN111491657A (enExample)
WO (1) WO2019079663A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240166694A1 (en) * 2021-03-19 2024-05-23 Tenza, Inc. Synthetic pre-protein signal peptides for directing secretion of heterologous proteins in bacillus bacteria
US20250382625A1 (en) * 2022-05-12 2025-12-18 Tenza, Inc. Synthetic pre-protein signal peptides for directing secretion of heterologous proteins in escherichia bacteria
DE102022119024A1 (de) * 2022-07-28 2024-02-08 INM - Leibniz-Institut für Neue Materialien gemeinnützige Gesellschaft mit beschränkter Haftung Neuartige genetische Werkzeuge
WO2024145571A2 (en) * 2022-12-30 2024-07-04 Tenza, Inc. Artificial secretion peptides for heterologous protein production
WO2025146497A1 (en) * 2024-01-05 2025-07-10 National University Of Singapore Methods for drug delivery
CN118813504B (zh) * 2024-09-19 2025-02-07 青岛诺和诺康生物科技有限公司 改善血栓和血管健康的卷曲乳杆菌及其制品和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002017357A (ja) * 2000-07-04 2002-01-22 Calpis Co Ltd アンカーペプチド、融合蛋白質、及び蛋白質の固定化方法
WO2011160062A2 (en) * 2010-06-17 2011-12-22 The Usa As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
AU2003276822A1 (en) 2002-03-08 2004-02-02 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
US20090226418A1 (en) 2005-08-19 2009-09-10 Leo Gerardus Frenken Food Products Comprising Probiotic Micro-Organisms and Antibodies
US20080051317A1 (en) 2005-12-15 2008-02-28 George Church Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
US20110104121A1 (en) 2008-05-21 2011-05-05 Wira Charles R Female Reproductive Tract and Anal Prophylaxes
GB0821729D0 (en) * 2008-11-28 2008-12-31 Plant Bioscience Ltd Composition and method for enhanced secretion of peptides and proteins from bacteria
WO2010077682A2 (en) 2008-12-08 2010-07-08 James Allen Lemke Treatment of hiv and aids using probiotic lactobacillus reuteri
EP2556085A2 (en) 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
GB2482536B (en) 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
CN104781401B (zh) * 2012-10-26 2018-06-05 独立行政法人产业技术综合研究所 人工生物发光酶
JP6835586B2 (ja) 2014-01-31 2021-02-24 シトムクス セラピューティクス，インコーポレイティド マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
CA3025020A1 (en) 2016-05-20 2017-11-23 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
KR102348734B1 (ko) * 2016-09-13 2022-01-07 인트랙슨 액토바이오틱스 엔.브이. 점막부착성 미생물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002017357A (ja) * 2000-07-04 2002-01-22 Calpis Co Ltd アンカーペプチド、融合蛋白質、及び蛋白質の固定化方法
WO2011160062A2 (en) * 2010-06-17 2011-12-22 The Usa As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions

Also Published As

Publication number Publication date
US11530433B2 (en) 2022-12-20
WO2019079663A8 (en) 2019-06-13
US20230257794A1 (en) 2023-08-17
EP3697428A1 (en) 2020-08-26
WO2019079663A1 (en) 2019-04-25
EP3697428A4 (en) 2021-11-24
KR20200077534A (ko) 2020-06-30
JP2021500035A (ja) 2021-01-07
US20200270666A1 (en) 2020-08-27
JP7330517B2 (ja) 2023-08-22

Similar Documents

Publication Publication Date Title
US20230257794A1 (en) Artificial secretion peptides for heterologous protein production
US9732143B2 (en) Methods and materials for enhancing functional protein expression in bacteria
US20090148408A1 (en) Lactobacilli expressing biologically active polypeptides and uses thereof
CN110913875A (zh) 程序化以在肿瘤细胞中产生免疫调节子和抗癌治疗剂的微生物
JP5787298B2 (ja) 膜に提示したタンパク質を特異的に認識するポリペプチドの調製方法
Ubah et al. Novel, anti-hTNF-α variable new antigen receptor formats with enhanced neutralizing potency and multifunctionality, generated for therapeutic development
CN105473609A (zh) 用于表达肽和蛋白的方法
JPWO2010104115A1 (ja) 膜タンパク質を特異的に認識するポリペプチドの調製方法
JP2024112828A (ja) 消化管系へのペイロード送達のための、ｂｔｎｌ３／８を標的とする構築物
US20240150440A1 (en) Constructs comprising single domain vhh antibodies against sars cov-2
CN114853880B (zh) Wt1抗原特异性t细胞受体及其抗肿瘤用途
CN113461810B (zh) 一种抗新型冠状病毒刺突蛋白的全人源单克隆抗体及其应用
CN106928365B (zh) 一种FAP纳米抗体Nb36
WO2021197212A1 (zh) 噬菌体药物蛋白展示系统及其应用
CN106928368B (zh) 一种FAP纳米抗体Nb57
US20210309984A1 (en) ChiA Enzyme
CN114380905A (zh) 靶向SARS-CoV-2RBD蛋白的鲨源纳米抗体、制备方法和应用
CN113234152A (zh) 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用
EP4332114A1 (en) Method for screening alpha beta-tcr heterodimer mutants
Rykov et al. Designing a cell surface display system of protein domains in lactobacilli based on S-Layer proteins of Lactobacillus brevis ATCC 367
JPWO2006126682A1 (ja) アルツハイマー病の予防・治療用ワクチン
CN120365416A (zh) 一种特异性结合甲型流感病毒血球凝集素的抗体
CN119020384A (zh) 一种利用大肠杆菌展示活性纳米抗体的方法及其应用
CN116917337A (zh) 来自病毒蛋白序列的转录活性复合物靶向癌症药物
CN115368459A (zh) 一种抗人MICA/B α3区二价纳米抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200804